| Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection DS Khoury, D Cromer, A Reynaldi, TE Schlub, AK Wheatley, JA Juno, ... Nature medicine 27 (7), 1205-1211, 2021 | 3897 | 2021 |
| Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection C Phetsouphanh, DR Darley, DB Wilson, A Howe, C Munier, SK Patel, ... Nature immunology 23 (2), 210-216, 2022 | 908 | 2022 |
| Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies WS Lee, AK Wheatley, SJ Kent, BJ DeKosky Nature microbiology 5 (10), 1185-1191, 2020 | 764 | 2020 |
| Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation LK Mackay, AT Stock, JZ Ma, CM Jones, SJ Kent, SN Mueller, WR Heath, ... Proceedings of the National Academy of Sciences 109 (18), 7037-7042, 2012 | 700 | 2012 |
| Minimum information reporting in bio–nano experimental literature M Faria, M Björnmalm, KJ Thurecht, SJ Kent, RG Parton, M Kavallaris, ... Nature nanotechnology 13 (9), 777-785, 2018 | 585 | 2018 |
| Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis D Cromer, M Steain, A Reynaldi, TE Schlub, AK Wheatley, JA Juno, ... The Lancet Microbe 3 (1), e52-e61, 2022 | 565 | 2022 |
| Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 JA Juno, HX Tan, WS Lee, A Reynaldi, HG Kelly, K Wragg, R Esterbauer, ... Nature medicine 26 (9), 1428-1434, 2020 | 471 | 2020 |
| Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with … SJ Kent, A Zhao, SJ Best, JD Chandler, DB Boyle, IA Ramshaw Journal of virology 72 (12), 10180-10188, 1998 | 422 | 1998 |
| Tuberculous meningitis: a 30-year review SJ Kent, SM Crowe, A Yung, CR Lucas, AM Mijch Clinical infectious diseases 17 (6), 987-994, 1993 | 396 | 1993 |
| Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells M Rigau, S Ostrouska, TS Fulford, DN Johnson, K Woods, Z Ruan, ... Science 367 (6478), eaay5516, 2020 | 390 | 2020 |
| Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 AK Wheatley, JA Juno, JJ Wang, KJ Selva, A Reynaldi, HX Tan, WS Lee, ... Nature communications 12 (1), 1162, 2021 | 377 | 2021 |
| Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection D Cromer, JA Juno, D Khoury, A Reynaldi, AK Wheatley, SJ Kent, ... Nature Reviews Immunology 21 (6), 395-404, 2021 | 281 | 2021 |
| Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies S Jegaskanda, ER Job, M Kramski, K Laurie, G Isitman, R de Rose, ... The Journal of Immunology 190 (4), 1837-1848, 2013 | 254 | 2013 |
| Circulating TFH cells, serological memory, and tissue compartmentalization shape human influenza-specific B cell immunity M Koutsakos, AK Wheatley, L Loh, EB Clemens, S Sant, S Nüssing, A Fox, ... Science translational medicine 10 (428), eaan8405, 2018 | 244 | 2018 |
| From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases EH Pilkington, EJA Suys, NL Trevaskis, AK Wheatley, D Zukancic, ... Acta biomaterialia 131, 16-40, 2021 | 234 | 2021 |
| A site of vulnerability on the influenza virus hemagglutinin head domain trimer interface S Bangaru, S Lang, M Schotsaert, HA Vanderven, X Zhu, N Kose, ... Cell 177 (5), 1136-1152. e18, 2019 | 229 | 2019 |
| Cytotoxic CD4 T cells—friend or foe during viral infection? JA Juno, D Van Bockel, SJ Kent, AD Kelleher, JJ Zaunders, CML Munier Frontiers in immunology 8, 19, 2017 | 226 | 2017 |
| Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques S Jegaskanda, JT Weinfurter, TC Friedrich, SJ Kent Journal of virology 87 (10), 5512-5522, 2013 | 224 | 2013 |
| Immunological principles guiding the rational design of particles for vaccine delivery KT Gause, AK Wheatley, J Cui, Y Yan, SJ Kent, F Caruso ACS nano 11 (1), 54-68, 2017 | 219 | 2017 |
| Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine Y Ju, WS Lee, EH Pilkington, HG Kelly, S Li, KJ Selva, KM Wragg, ... Acs Nano 16 (8), 11769-11780, 2022 | 209 | 2022 |